PNT Stock Overview
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
POINT Biopharma Global Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.22 |
| 52 Week High | US$10.98 |
| 52 Week Low | US$5.23 |
| Beta | 0.059 |
| 1 Month Change | 6.96% |
| 3 Month Change | -26.18% |
| 1 Year Change | 14.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.93% |
Recent News & Updates
Shareholder Returns
| PNT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | 0.7% | 2.3% |
| 1Y | 14.6% | 7.1% | -9.7% |
Return vs Industry: PNT exceeded the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: PNT exceeded the US Market which returned -8.5% over the past year.
Price Volatility
| PNT volatility | |
|---|---|
| PNT Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PNT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: PNT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 72 | Joe McCann | https://www.pointbiopharma.com |
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies.
POINT Biopharma Global Inc. Fundamentals Summary
| PNT fundamental statistics | |
|---|---|
| Market Cap | US$762.76m |
| Earnings (TTM) | -US$79.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs PNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$79.17m |
| Earnings | -US$79.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PNT perform over the long term?
See historical performance and comparison